Clinical Trial: Telavancin (TD 6424, ARBELIC™) for Treatment of Uncomplicated Staphylococcus aureus Bacteremia


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Telavancin (TD 6424, ARBELIC™) for Treatment of Uncomplicated Staphylococcus aureus Bacteremia

This study is currently recruiting patients.

Sponsored by:	Theravance
Information provided by:	Theravance

Purpose

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

Condition	Treatment or Intervention	Phase
Gram-Positive Bacterial Infections	Drug: Telavancin (TD-6424, Arbelic)	Phase II

MedlinePlus related topics: Bacterial Infections

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous ARBELIC™ (TD 6424) for Treatment of Uncomplicated Staphylococcus aureus Bacteremia

Further Study Details:

Expected Total Enrollment: 60

Study start: June 2003

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

Uncomplicated Staphylococcus aureus bacteremia that is healthcare associated.

Location and Contact Information

Michigan
William Beaumont Hospital, Royal Oak, Michigan, 48073, United States; Recruiting

Christopher F. Carpenter, MD 248-551-7941

More Information

Study ID Numbers: I6424-203a; ASSURE
Record last reviewed: October 2004
Record first received: June 9, 2003
ClinicalTrials.gov Identifier: NCT00062647
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services